-
Period: to
History
-
Quintiles is incorporated
Founded in a trailer in the University of North Carolina by Dennis Gillings, a professor of biostatistics. -
Opens UK office
Quintiles opesn its UK operations to serve customers in Europe. -
Pacific and Ireland units established
Quintiles Pacific and Quintiles Ireland established -
German unit and US lab
Adds unit in Germany and sets up Quintiles Laboratories in Atlanta, Georgia -
Opens Atlanta lab
Quintiles opens in Atlanta, Georgia. -
Sets up in Japan
Quintiles establishes operations in Asia, opening in Tokyo -
Grows
Quintiles buys Innovex and BRI International becoming the world's largest CRO -
Adds consulting offering
Quintiles establishes its Consulting practice with the acquisition of a globally recognized health care policy research and management consulting -
Goes Public
Quintiles goes public, completing successful secondary stock offering. -
First CRO to break $1bn revenue mark
Quintiles is the first company in industry to break the $1bn mark, when it reports net revenues of $1.2bn. -
Buys US dev facility
Quintiles acquires Hoechst Marion Roussel's drug development facility in Kansas City -
Joins the S&P 500 index
Quintiles joins the S&P 500 Index. -
Partners witl Eli Lilly
Quintiles signs landmark partnership agreement with Eli Lilly and Company to commercialize Cymbalta -
Becomes a private firm
Quintiles directors agree to merge with Pharma Services Holdings and the CRO becomes a private company. -
Quintiles moves to Overland Park
Quintiles moves to a new facility in Overland Park with a 150-bed Phase I Unit, and room for up to 200 more employees. -
Forms eclinical JV with Thermo Fisher
-
Expands US central lab
-
Attracts new PE investors
-
Buys central lab in Japan
-
New HQ in North Caroilina
-
Calls for industry change on sites
-
Looks at Africa
-
Selects invivodata for ePRO
-
-
Contract pathology in China
-
Translational Med site in UK
-
Move Japan lab
-
Calls Asian Outsourcing strategic
-
First Asian prime site
-
New global IT centre
-
Phase I unit in India
-
-
Looks at takeovers and strategic deals
-
Forms biosimilars JV
-
Builds in South Korea
-
Halts financing plan
-
Buys regulatory services biz in Italy
-
Eyes Russian Market
Russian market at tipping point syays Quintiles Quintiles tells Outsourcing-pharma.com about opportunities in Russia -
Observational research and market access M&As
-
Premier's financing partnership approach
-
Invests in China and Biomarkers
-
CEO talks to Outsourcing-pharma.com
-
Names new CEO
-
Wins Almirall contract
-
Another prime site established
Give Comprehensive prime site status Quintiles grants Comprehesive Clinical Development prime site status -
Sets up Scotish prime site
-
First trial in Indonesia
-
S&P prteditcs Quintiles will grow market share
-
Declines to comment about IPO
